Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Increases By 16.2%

Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Rating) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 853,900 shares, a growth of 16.2% from the February 13th total of 735,100 shares. Approximately 2.9% of the shares of the company are sold short. Based on an average trading volume of 402,600 shares, the short-interest ratio is currently 2.1 days.

Aligos Therapeutics Stock Down 2.9 %

Shares of NASDAQ ALGS opened at $1.32 on Monday. The stock has a market capitalization of $56.52 million, a price-to-earnings ratio of -0.58 and a beta of 2.50. The stock’s fifty day simple moving average is $1.62 and its 200 day simple moving average is $1.26. Aligos Therapeutics has a 52-week low of $0.84 and a 52-week high of $2.99.

Wall Street Analyst Weigh In

ALGS has been the topic of a number of research reports. Piper Sandler boosted their price objective on Aligos Therapeutics from $3.00 to $7.00 in a research note on Monday, January 16th. Jefferies Financial Group raised Aligos Therapeutics from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $2.50 to $3.00 in a research note on Friday, January 6th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. PDT Partners LLC purchased a new position in shares of Aligos Therapeutics during the first quarter valued at $57,000. AQR Capital Management LLC purchased a new position in Aligos Therapeutics in the second quarter valued at about $58,000. Prelude Capital Management LLC purchased a new position in Aligos Therapeutics in the first quarter valued at about $58,000. Rockefeller Capital Management L.P. purchased a new position in Aligos Therapeutics in the third quarter valued at about $85,000. Finally, Mirabella Financial Services LLP purchased a new position in Aligos Therapeutics in the first quarter valued at about $88,000. Hedge funds and other institutional investors own 64.53% of the company’s stock.

About Aligos Therapeutics

(Get Rating)

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB.